These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23431071)

  • 1. The treatment of minimal change disease in adults.
    Hogan J; Radhakrishnan J
    J Am Soc Nephrol; 2013 Apr; 24(5):702-11. PubMed ID: 23431071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
    Waldman M; Crew RJ; Valeri A; Busch J; Stokes B; Markowitz G; D'Agati V; Appel G
    Clin J Am Soc Nephrol; 2007 May; 2(3):445-53. PubMed ID: 17699450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of enteric-coated mycophenolate sodium in the treatment of relapsing and steroid-dependent minimal change disease.
    Siu YP; Tong MK; Leung Ka; Kwan TH; Au TC
    J Nephrol; 2008; 21(1):127-31. PubMed ID: 18264946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea.
    Lee HY; Kim HS; Kang CM; Kim SG; Kim MJ
    Clin Nephrol; 1995 Jun; 43(6):375-81. PubMed ID: 7554521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with
    Medjeral-Thomas NR; Lawrence C; Condon M; Sood B; Warwicker P; Brown H; Pattison J; Bhandari S; Barratt J; Turner N; Cook HT; Levy JB; Lightstone L; Pusey C; Galliford J; Cairns TD; Griffith M
    Clin J Am Soc Nephrol; 2020 Feb; 15(2):209-218. PubMed ID: 31953303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of corticoresistant idiopathic nephrotic syndrome in the adult: minimal change disease and focal segmental glomerulosclerosis.
    Meyrier A; Simon P
    Adv Nephrol Necker Hosp; 1988; 17():127-50. PubMed ID: 3124536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of steroid-dependent minimal change-nephrotic syndrome with mycophenolate mofetil].
    Noroña B; Valentín M; Gutiérrez E; Praga M
    Nefrologia; 2004; 24(1):79-82. PubMed ID: 15083963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of corticoid-resistant nephrotic syndrome: a still unresolved problem].
    Damiani B; Giani M; Consalvo G; Carcano A; Ghio L; Edefonti A
    Pediatr Med Chir; 1995; 17(1):9-15. PubMed ID: 7739938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome.
    Schweda F; Liebl R; Riegger GA; Krämer BK
    Nephrol Dial Transplant; 1997 Nov; 12(11):2433-5. PubMed ID: 9394341
    [No Abstract]   [Full Text] [Related]  

  • 10. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.
    Li H; Shi X; Shen H; Li X; Wang H; Li H; Xu G; Chen J
    Clin Ther; 2012 May; 34(5):1112-20. PubMed ID: 22503105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of immunosuppressive agents in the treatment of nephrosis in children].
    Cochat P; David L; Parchoux B; Freycon MT; Larbre F
    Pediatrie; 1987; 42(7):519-26. PubMed ID: 3328154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nephrotic syndrome. Official report of the Section of Pediatric Nephrology].
    García García L; Martín Govantes J; Navarro Torres M; Simón González J; Vallo Boada A
    An Esp Pediatr; 1982 Oct; 17(4):354-8. PubMed ID: 7158884
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease.
    Zhou J; Zhang Y; Liu G; Li J; Xu R; Huang J
    Clin Nephrol; 2013 Aug; 80(2):121-9. PubMed ID: 23458173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy].
    Branten AJ; Wetzels JF
    Ned Tijdschr Geneeskd; 1998 Dec; 142(52):2832-8. PubMed ID: 10065257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipoid nephrosis in childhood].
    Niaudet P
    Rev Prat; 2003 Nov; 53(18):2027-32. PubMed ID: 15008217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
    Munyentwali H; Bouachi K; Audard V; Remy P; Lang P; Mojaat R; Deschênes G; Ronco PM; Plaisier EM; Dahan KY
    Kidney Int; 2013 Mar; 83(3):511-6. PubMed ID: 23325085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of nephrotic syndrome in children and controlled trials.
    Filler G
    Nephrol Dial Transplant; 2003 Aug; 18 Suppl 6():vi75-8. PubMed ID: 12953047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies.
    Brodehl J
    Eur J Pediatr; 1991 Apr; 150(6):380-7. PubMed ID: 2040345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features and treatment response in nephrotic IgA nephropathy with minimal change disease.
    Qin J; Yang Q; Tang X; Chen W; Li Z; Mao H; Jiang Z; Huang F; Yu X
    Clin Nephrol; 2013 Jan; 79(1):37-44. PubMed ID: 22948116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal change (steroid sensitive) nephrotic syndrome in children: new aspects on pathogenesis and treatment.
    Oh J; Kemper MJ
    Minerva Pediatr; 2012 Apr; 64(2):197-204. PubMed ID: 22495193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.